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This review summarizes recent literature on advances regarding renal and ureteral calculi, with particular focus in
areas of recent advances in the overall field of urolithiasis. Clinical management in everyday practice requires a
complete understanding of the issues regarding metabolic evaluation and subgrouping of stone-forming patients,
diagnostic procedures, effective treatment regime in acute stone colic, medical expulsive therapy, and active stone
removal. In this review we focus on new perspectives in managing nephrolitihiasis and discuss recentadvances,
including medical expulsive therapy, new technologies, and refinements of classical therapy such as shock wave
lithotripsy, give a fundamental modification of nephrolithiasis management. Overall, this field appears to be the
most promising, capable of new developments in ureterorenoscopy and percutaneous approaches. Further
improvements are expected from robotic-assisted procedures, such as flexible robotics in ureterorenoscopy.
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Introduction
Treating patients with urolithiasis is part of the everyday
urological practice. An excellent clinical management
involves a complete knowledge of issues regarding meta-
bolic evaluation and subgrouping of stone-forming
patients, diagnostic procedures, an effective treatment
regime in acute stone colic, medical expulsive therapy,
and active stone removal. In the 1980s, results of revolu-
tionary technology such as shock wave lithotripsy (SWL)
dramatically changed the therapeutic panorama of lithia-
sis, while open surgery was disappearing. Today the
most invasive procedure for patients with significant
stone burden is percutaneous nephrolithotomy (PNL).
Furthermore, over the past decade, profound advances
in endoscope design, durability, and accessories
revolutionized the field of minimally invasive therapy.
Here, we review recent advances in the management
of stone disease. We have specifically focused on the
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e) surgery, endoscopic procedures, and robot assisted
procedures.Epidemiology and risk factors
International epidemiological data suggest that the inci-
dence and prevalence of stone disease is increasing [1].
Recent data analysis show a higher prevalence in white
population and stronger associations of prevalent kidney
stone disease with increased triglycerides, older age, and
gallstone disease in African Americans compared to
whites, whereas male gender showed stronger associ-
ation in whites; a dramatic increase of prevalence in fe-
male populations is also observed [2]. There was a
significant increase in the incidence of kidney stones in
children between 1996 and 2007 [3].
Recent papers focused on the most prominent meta-
bolic issues of urolithiasis affecting an ever increasing
number of people in developed countries: obesity, dia-
betes mellitus, hyperuricemia, and metabolic syndrome
[4-9]. All these pathologic entities are strongly correlatedhis is an Open Access article distributed under the terms of the Creative
mons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
al work is properly cited.
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found not to correlate with increased risk of stone for-
mation, whereas calcium and Vitamin D supplementa-
tion played a pivotal role in stone-former patients [10].
The protecting role of adequate diet characterized by a
high intake of fluids, fruits, and vegetables, a low con-
sumption of salt and protein and a balanced intake of
calcium, fats, and carbohydrates constitutes an effica-
cious approach to the prevention and treatment of this
illness [5,11].
Metabolic evaluation and medical therapy
Identification of metabolic risk factors and correct inter-
pretation of collected data play an important role in
managing stone patients and preventing recurrence
wherever possible. The new edition of the European As-
sociation of Urology (EAU) Guidelines on Urolithiasis
includes a useful system of subgrouping stone-forming
patients into different categories, based on the type of
stone and the severity of symptoms of the disease and
also includes a simplified overview of the principles of
analytical work-up [12]. Other authors underlined the
fundamental role of metabolic work-up in high-risk
stone formers [13] and children [14,15]. Still controver-
sial is the role of urology specialists in fields where the
nephrologist often plays a major role.
Since patient compliance largely influences medical treat-
ment outcomes, adequate patient information regarding
drinking and dietary recommendations plays a major role
[12,13,16]. Dietary and drinking advice should always be
considered before any pharmacological therapy. Correct
dietary regimes should never be abandoned even when a
pharmacological approach is started.
Various therapeutic tools were used in order to reduce
the risk of recurrent calcium stones, that may result in
stabilization of stone disease and prevention of the need
for further surgical procedures for stone removal [16,17].
Turk et al. gives a brilliant effort to summarize all the
suggested treatments and recommendations [12].
Alkaline citrate
Alkalinizations of tubular cells is the most important
factor that results in an increased citrate excretion with
only a small fraction of citrate preparations excreted
with urine. Citrate calcium chelation reduces ion-activity
products of both calcium oxalate and calcium phosphate
and inhibits growth and aggregation/agglomeration of
these crystals [12]. Thus citrate dilate lithogenesis
promotes urinary alcalinization (reducing uric acid
supersaturation) and increases cystine solubility. Citrate
supplementation plays a fundamental role particularly in
patients with hypocitraturia, which constitutes 20% of all
stone formers [12,18,19]. Various citrate preparations
(sodium potassium citrate, potassium citrate, potassiummagnesium citrate, potassium bicarbonate, and sodium
bicarbonate) were known to reduce the risk in stone-
former patients. Findings based on randomized studies
show that potassium citrate has a greater potential for
preventing recurrence than does sodium potassium cit-
rate [20-26]. When oral intake of citrate preparations is
unpleasant for the patient, lemon or orange juice could
be a valuable option, the latter being a better alkalinising
and citraturic agent [21-23]. Citrate supplementation is
also useful to considerably decrease stone formation risk
that is correlated with prolonged bed rest [20].
Thiazides and thiazide-like agents
After the initial report by Yendt in 1970 we have more
than 30 years of clinical experience with thiazides for
calcium stone prevention [27,28]. The aim of thiazide
treatment is to reduce calcium excretion in hypercalciuric
patients (which constitutes around half of stone formers).
This effect is thought to be mediated by an increased
reabsorption of calcium in the proximal and distal part
of the nephron [27-29]. Idiopathic hypercalciuria is a
common disorder in children and can present with a
range of clinical presentations such as hematuria, voiding
dysfunction, flank pain, abdominal pain, nephrolithiasis,
urinary tract infection and decreased bone mineral
density. Dietary modifications are often sufficient in the
management of hypercalciuria. If the symptoms persist
or a rare monogenic disorder is present, consideration
should be given to medical treatment with a thiazide
diuretic and/or citrate therapy [30]. Hydroclorothiazide
is usually given at a 25–50 mg dosage once or twice
daily. A supplementation with potassium salt (i.e., po-
tassium citrate 3.5–7 mmol twice daily) is needed to
counterbalance the thiazide-induced potassium loss and
hypocitraturic effect [12,31,32]. Thiazide treatment
has considerable metabolic side effects: unmasking
normocalcaemic hyperparathyroidism, development of
diabetes and gout, and erectile dysfunction contribute
to a limited patient compliance (50–70%) and high
dropout rate [12,16,33].
Allopurinol
A xantine-oxidase inhibitor that prevents uric acid pro-
duction from purine, allopurinol is a commonly used and
usually well tolerated anti-gout drug [34]. In urolithiasis
patients, treatment is given to counteract the formation of
calcium oxalate stones. Allopurinol use in this pathologic
condition was introduced following demonstration of a
relationship between hyperuricosuria and calcium oxalate
stone formation. Allopurinol has been used clinically in
patients with or without hyperuricosuria. During the
1980s, Miano et al. [35] performed a placebo-controlled
study where treatment with allopurinol was given to
hyperuricosuric, calcium oxalate stone formers. Results
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patients were free of recurrent stones compared with 45%
of the placebo group. Other randomized studies where
patients were not selected for hyperuricosuria found no
effect on stone formation, thus recent published EAU
Guidelines [12] suggest that allopurinol “might be useful
for treating patients with hyperuricosuric calcium stone
formation” but it “cannot be recommended for patients
with other biochemical abnormalities”. A new potential
pharmacologic therapy for recurrent stone disease is
described by Goldfarb et al. Febuxostat, a nonpurine
inhibitor of xanthine oxidase (also known as xanthine
dehydrogenase or xanthine oxidoreductase) may have
advantages over allopurinol and is being tested in a similar
protocol, with the eventual goal of determining whether
urate-lowering therapy prevents recurrent calcium stones
[36]. The major drawback of allopurinol treatment is the
occurrence of severe side effects reported with high doses.
Adverse effects include Steven-Johnson or Lyell syn-
drome, vasculitis, hepatitis, and renal failure. Allopurinol
should be discontinued immediately in case of cutaneous
rush [34].
Phytotherapy
Various herbal preparations have been used in urolithiasis
therapy since ancient times [37]. Grases et al. evaluated the
antilithiasic activity of herbal extract and antioxidant
flavonoids (catechin and epicatechin) in rats with ethylene
glycol induced lithiasis. Herbal preparations and flavonoids
showed the ability to prevent papillary and intratubular
calcification in the kidney [38]. Phytotherapy was probably
clinically efficacious in hastening stone expulsion (<8 mm)
without any observed adverse events [39]. Other herbal
preparations show efficacy in stone expulsion after SWL
(see further).
Diagnostic procedures and interventional radiology
Computed tomography
Non-contrast computed tomography (NCCT) has been
introduced during recent years and has become the
well-recognized gold standard and most clinically useful
tool for diagnosis of urolithiasis [40-42]. One great ad-
vantage is its ability to detect alternative diagnoses and
to identify uric acid and xanthine stones that are radio-
lucent on plain film. This method shows superior [43]
specificity and sensitivity compared with Intra Venous
Pyelography urography. Combined IVU and CT study
allowed correct diagnosis of the underlying cause of
delayed excretion or upper urinary tract dilatation in
97% of cases, reducing time and radiation [44].
Still controversial is its role during follow-up for treated
urolithiasis patients and those on observation protocol.
Potretzke and Monga [45] suggested that follow-up
should be done with plain film radiography if the stone isradio-opaque. Surveillance in children, uric acid stone-
formers, and cystine stone-formers should be performed
with ultrasonography. Pediatric patients treated for symp-
tomatic urolithiasis could have completed their evaluation
and treatment without undergoing NCCT in nearly 90%
of the cases [46].
The usefulness of plain radiography is still under de-
bate. Lamb et al. [47] determined the proportion of
stone patients in which management is altered by the in-
terpretation of plain abdominal radiographs (KUB). They
observed that on the basis of KUB findings a significant
change in patient management occurred. Data shows
that KUB offers a significant advantage in treatment
planning once the diagnosis has been established by
NCCT because of information it provides regarding
radio-opacity as well stone size and visibility. Johnston
et al. agree if the stone is visible on CT scout film, then
the decision to use KUB for follow-up can be made. This
minimizes radiation exposure and other costs [48]. But
stone features cannot be delivered by NCCT alone.
NCCT size estimation of distal ureteral stones versus
their actual size was investigated by Kishore and
coworkers [49]. Findings show that CT is a poor pre-
dictor of the largest stone dimension for distal calculi.
Thus caution should be used in patient counseling on
the rate of spontaneous passage. Experimental studies
using dual energy CT images (ie, scanners that can sim-
ultaneously acquire images at different energies) try to
offer a routine clinical practice to estimate urinary stone
composition based on the density of all constituent
voxels [50]. In recent study, the introduction of dual-
energy computed tomography systems has significant
and unique applications for urologists. Imaging data
from these scanners can be used to evaluate composition
of urinary calculi [51].Ultrasound
Ultrasonography is a well-recognized diagnostic tool
and is usually the first imaging modality during diagnos-
tic work-out. Ultrasonography is furthermore a safe and
useful option in both the pediatric and pregnant
populations, for whom it constitutes the imaging mo-
dality of choice. Further studies refined the diagnostic
usefulness of ultrasonography in the localization of
distal ureter calculi by imaging transrectally and
transvaginally [52,53]. Mitterberger et al. placed ultra-
sound transducers with three-dimensional and volume
scanning capabilities, transvaginally in female patients
and transrectally in males. The authors were able to ex-
hibit stones with 100% sensitivity, improving diagnosis
in patients examined with transabdominal ultrasound
and intravenous urogram (IVU), which together had
81% sensitivity.
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facilitate spontaneous clearance of kidney stones and
increased clearance of residual stone fragments after
surgical management. Shan et al. present a novel
method and device to reposition kidney stones using
ultrasound radiation force delivered by focused ultra-
sound and guided by ultrasound imaging. Feasibility of
repositioning stones was investigated by implanting
artificial and human stones into a kidney-mimicking
phantom that simulated a lower pole and collecting
system. During experiment, stones were located by
ultrasound imaging and repositioned by delivering short
bursts of focused ultrasound. Stones were seen to move
immediately after delivering focused ultrasound and
successfully repositioned from the lower pole to the
collecting system [54].
Radiation exposure
Patients undergoing diagnostic imaging may receive ex-
cessive doses of radiation during initial diagnostic and
follow-up evaluations. Renal collecting systems can be
illustrated more precisely with the advent of multi-
detector row CT through thinner slices, high speed
acquisitions, and enhanced longitudinal spatial reso-
lution resulting in improved reformatted coronal images.
On the other hand, a significant increase in exposure
to ionizing radiation, especially in the radiosensitive
organs, such as the gonads, is a concern with the
increased utilization of urinary tract CT [55]. Few stud-
ies investigated the effective radiation dose associated
with an acute stone episode and short-term follow-up.
Ferrandino et al. in a single-institution study found that
205 patients received a dose greater than 20 mSv. John
et al. found a median radiation dose per stone episode
of 5.3 mSv, with higher doses in those with renal stones
and those who required CT scans and other interventions.
Ferrandino suggests that urologists must be cognizant of
the radiation exposure to patients and seek alternative
imaging strategies to minimize radiation dosages during
acute and long-term stone management. [56,57]. In the
US, around 60 million CT scans are performed every year
[43], raising concern about the amount of radiation
delivered. Thus different lower-dose radiation protocols
were proposed [56-60]. Results show a high efficacy of
lower-dose CT. Unfortunately, studies defined standard
and low-dose protocols differently. A standard protocol
uses about 180 mAs and low-dose protocol would be
performed with about 30 mAs. Furthermore, a major role
is played by the slice thickness and therefore the patient’s
time exposure. But low-dose protocols use thicker slices
than standard protocols, raising the risk of failure in
detecting smaller stones. Memarsadeghi et al. determined
that overlapping 3–5 mm slices could be a sufficient
parameter for detection of significant urinary stones [61].Ciaschini et al. found no significant differences with low
dose (−25% and −50%) examinations for the detection of
calculi greater than 3 mm [62]. Jellison et. al and Jin et al.
compared ultra low dose and conventional computerized
tomography protocols for detecting distal ureteral calculi
[63] and renal calculi [64] in a cadaveric model. Jellison’s
ultra low dose computerized tomography protocols
detected distal ureteral calculi in a fashion similar to that
of conventional computerized tomography protocols in a
cadaveric model. These protocols may decrease the radi-
ation dose up to 95%. Jin decreased the tube charge from
100 to 30 mAs, resulted in similar detection of renal
stones respect conventional CT. Dose reduction is also
important in pediatric settings. The use of the 80 mA set-
ting for all children and 40 mA for children weighing
50 kg or less does not significantly affect the diagnosis of
pediatric renal stones [65].
SWL
SWL has changed dramatically the management of
urolithiasis since the early 1980s. Widespread use of the
technology, development of smaller devices, modified
indication, and the lower cost of the procedure
revolutionized the approach to stone patients. The large
amount of sessions performed in the last 25 years
allowed for the collection of important data on the
indications, contraindications, and adverse effects of the
procedure. Krambeck et al. [66] collected data regarding
diabetes and hypertension associated with SWL
performed with a Dornier HM3 lithotripter. Hyperten-
sion incidence was significantly correlated with bilateral
procedures, while diabetes was correlated with shock
wave number and frequency. The authors suggest that
unobserved micro-trauma on the pancreas and kidney
could explain the incidence of diabetes and hyperten-
sion. On the other side recent study by Chew et al. [67]
compare the prevalence of hypertension and diabetes
mellitus (DM) in patients treated with an unmodified
HM-3 lithotripter (USWL) and a second-generation
modified HM-3 lithotripter (MSWL) 20 years ago at
their centre in Vancouver with that in the provincial
population. No association between lithotripsy and the
development of either DM or hypertension in a multi-
variate analysis. They postulate that the development of
renal calculi in our subjects is more indicative of an
overall metabolic syndrome where there is increasing
evidence that patients with kidney stones get hyperten-
sion and diabetes and vice-versa. The development of
these diseases is not related to shockwave lithotripsy,
but rather to a systemic metabolic dysfunction.
Lee et al. in 2011 propose SWL treatment at a frequency
of 60 shocks/min yielded better outcomes, such as a lower
number of SWL sessions, and had an increased success
rate compared with SWL at 120 shocks/min. On the
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Therefore, SWL treatment at a frequency of 60 shocks/
min could improve treatment efficacy more than that
for SWL at 120 shocks/min. [68]. Mazzucchi et al.
found no significant differences in the stone-free and
complication rates were observed by reducing the total
number of impulses from 4000 to 3000 and the fre-
quency from 90 to 60 impulses per minute [69]. Chacko
et al. favors a frequency reduction, arguing that 90 sw/
min treatment gave better results in terms of stone
fragmentation compared to 120 sw/min [70]. Further
reduction of frequency (30 sw/min) showed a protective
effect on renal vessels in an animal model [71]. Further-
more, Tham et al. observed optimal fragmentation by
using a short delay time (20 μs) between shock waves [72].
In animal models, stepwise power increases (18–20–
22 kV) during treatment gave better results in terms of
stone comminution compared with power decreases or
leveling (96.5% vs. 89% vs. 87.6%, respectively). More-
over, Willis et al. proposed a “pre-treatment” of the kid-
ney with low-energy shock waves (12 kV) in order to
reduce renal injury [73,74].
Nomograms were introduced by Kanao et al. correlating
stone size, location, and numbers to predict stone-free
rates after the procedure using a Dornier Lithotripter
D [75]. Recently, Nakajiima and Kanao validated the
nomograms, finding a remarkable area under the curve
(AUC) value of 0.725 [76]. This remarkable effort to
predict outcome was until now limited to the Dornier ma-
chine. Vakalopoulos [77] avoided this gap by developing a
mathematical model to predict extracorporeal shockwave
lithotripsy outcomes where predictive equations can be
created for different lithotripters. Wiesenthal JD et al.
developed a comprehensive nomogram to predict renal
and ureteral stone shock wave lithotripsy outcomes,
dependent on patient and stone related factors. This
factors included stone location, were age, body mass
index, stone size, mean stone density (p < 0.01) and skin
to stone distance [78].
Shen et al. Perform a systematic review to assess the
necessity and complications of DJ stenting before extracor-
poreal shock wave lithotripsy in the management of upper
urinary stones. The systematic review suggested significant
advantages of stenting before extracorporeal shock wave
lithotripsy compared to in situ extracorporeal shock wave
lithotripsy in terms of Steinstrasse. However, stenting did
not benefit stone-free rate and auxiliary treatment after
extracorporeal shock wave lithotripsy, and it induced more
lower urinary tract symptoms [79]. El Assmi found that the
presence of hydronephrosis does not affect success rates for
distal ureteral stones but increases the number of
treatments needed to obtain stone clearance [80].
Recent studies showed the usefulness of CT imaging in
predicting fragility and consequently outcomes after SWL.Such imaging could also offer a considerable amount of
information regarding intrarenal anatomy (i.e., lower pole
calyx orientation), stone location, and stone composition.
Studies by Alon et Garcia Marchinena et al. attempt to
characterize stone composition with CT in order to have
an indication in the management of calculi suggesting a
first-line endoscopic therapy instead of SWL [81,82].
Furthermore, the risk of SWL failure is significantly
related to increased radiodensity (signal attenuation)
both in vitro and in vivo. Cystine, calcium oxalate mono-
hydrate, and brushite stones are least likely to be
fragmented by SWL [83-86].
Post-SWL therapy
An extensive meta-analysis of medical therapies could
be found in the paper by Shuller et al. and Micali
and coworkers [16,87]. The latter investigated the role
of Phyllanthus niruri (a plant belonging to the
Euphorbiaceae family used in Brazilian folk medicine by
patients with urolithiasis) in SWL and found a positive
correlation with lower calyx stone expulsion [88].
The same author [89] and Zheng et al. [90] explore
the efficacy of expulsive therapy using nifedipine or
tamsulosin, both associated with ketoprofene, after SWL
of ureteral stones. They found that nifedipine and
ketoprofene association play a significant role in increas-
ing stone free rates for the proximal and middle ureter
(85.7% vs. 51.7%) and that tamsulosin and ketoprofen
increase stone free rates in distal ureter stones (82.1% vs.
57.1%). Falahatkar S et al. [91] study the role of
tamsulosin as adjunctive therapy after extracorporeal
shock wave lithotripsy (ESWL) in 150 patients with 4–
20 mm in diameter renal and ureteral stones. Th
patients was shared 71 in control group and 70 in case
group, treated with Tamsulosin: thei found a statistically
significant difference in time of stone passage from onset of
treatment (between 20th and 30th day in control group
and between 10th and 20th day (50%) in case group after
ESWL). Sighinolfi et al. [92] found that treatment with
Tamsulosin after ESWL increases fragments expulsion rate
of renal calculi also.
As seen above, citrate supplementation could play an
important role in expulsive therapy after SWL. In a study
conducted on 96 hypocitraturic children who underwent
SWL potassium citrate showed a significant role in
decreasing recurrence (7.6% in citrate arm vs. 34.6% in
placebo) agglomeration of residual fragments [25].
SWL vs. URS
Debate over the most favorable method still continues
and probably will continue for decades. Kijvikai et al.
[93] try to offer some balanced consideration on the
better treatment for distal ureteral stones. SWL and
URS (ureteroscopic lithotripsy) are both considered to
Figure 1 The DUR-D (Olympus) digital and flexible ureteroscope.
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>10 mm have better outcomes with endoscopy (73% vs.
67%). Aboumarzouk OM et al. [94] agree that, compared
with ESWL, ureteroscopic removal of ureteral stones
achieves a greater stone-free state, but with a higher com-
plication rate and longer hospital stay. Furthermore, URS
plays a unique role during pregnancy or in patients with
uncontrolled blood coagulation [93,95].
In conclusion, SWL revolutionized urolithiasis therapy
and is often the treatment of choice for many ureteral
and renal stones. Moreover, SWL is related to low com-
plication rates. But a balanced choice should always
include patient consideration [96].
Digital endoscopes
At the beginning of this century, ureteroscopy received a
new impulse thanks to novel technological refinements
such as miniaturization of scope profile, improved man-
euverability, and optimized accessory instrumentation.
Currently available flexible ureteroscopes have an aver-
age tip diameter of about 6.9–7.5 Fr and a mid-shaft
diameter of 7.5–9.0 Fr and can be inserted in an intra-
mural ureter without active dilation in most cases [97].
Image quality was also improved by incorporating an
optical chip such as a CMOS (complimentary metal
oxide semiconductor) or CCD (charge-couple device) at
the tip of the ureteroscope together with distal LED light
and image processing capabilities. Digital ureteroscopes
eliminate the honeycomb effect, and deflection is compar-
able to traditional fiber-optic endoscopes. In September
2006, Gyrus-ACMI (Southboro, Massachusetts, USA) was
the first to introduce a ureteroscope incorporating this
technology: the DUR-D ureteroscope (Figure 1). Pre-
liminary reports indicate that the new-generation flex-
ible ureterorenoscopes are more durable than previous
ones [98,99]. All these enthusiastic reports should be
counterbalanced by an awareness of some disadvantages
of the new-generation endoscopes. Rigid and flexible
digital ureteroscopes are larger in diameter compared to
their analog counterparts, and digital technology has
higher costs. Thus more research is necessary to evaluate
the true advantage of digital technology for ureteroscopy
[100,101]. Undoubtedly, images produced by digital
endoscopes such as DUR-D are of outstanding quality.
Deflection capability is also an important issue. The
Storz FlexX2 Wolf Viper allows a 270 deflection in both
directions, while the Olympus P5 allows 270 in one dir-
ection and 180 in the other. The DUR 8-elite
ureteroscope (ACMI) was the first to offer dual primary
and secondary active tip deflection that totals 270. Pre-
liminary reports suggest that secondary deflection is ne-
cessary in approximately 20–29% of cases [102-104],
particularly with regard to lower pole access. Although
expensive, the holmium: YAG laser is actually the bestintracorporeal lithotripter for the ureter and the bench-
mark for other energy sources [105-107].
Accessories device
The ideal basket should be flexible, durable, atraumatic,
easily deployed/disengaged/disassembled, and of min-
imal impact on fluid inflow and tip deflection [108].
Thus, the ideal basket simply does not exist until now.
Despite marketing efforts to introduce the “perfect”
basket, comparison of four popular basket designs
suggested that the more complex wire configurations
and deflection capabilities offered no advantage over the
simple Cook N-Circle nitinol basket [108,109] (Figures 2
and 3).
PNL
International epidemiological data suggest that the inci-
dence and prevalence of stone disease is increasing and
the number of diagnoses and procedures relating to kid-
ney stone disease has increased significantly in the last
10 years in the UK [1]. Since the introduction of SWL
during the 1980s and development of endoscopic
techniques, open surgery is rapidly disappearing. Now-
adays PNL represents the most invasive procedure for
urolithiasis in significant stone burden patients. In the
US and UK, PNL experienced a rapid increase while
open surgery is showing a dramatic decreas [1,110].
Percutaneous access is the method of choice in stag-
horn and complex renal stones with diameters >2 cm
Figure 2 Cook N-Circle nitinol basket.
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Debates over patient position (prone or supine) and
SWL efficacy versus PNL take place in many journals.
PNL is indicated as the first-choice treatment in stag-
horn and complex renal stones >2 cm and for lower
calyx stones >1 cm [112].
Patient position
Recent studies proposed and popularized the Valdivia
Uria supine position for PNL. Valdivia Uria’s original
paper dated to 1987 and more than 557 have been
performed since then. According to the author, the
advantages of the position are a direct and easily accessFigure 3 Cook N-Circle nitinol basket on flexible ureteroscope.to anterior oriented calyces, easier access to the bladder,
and better stone free rates in comparison to the prone
position [113]. A recent review summarized the
arguments for and against prone and supine percutan-
eous nephrolithotomy: the prone position is associated
with a decrease in the cardiac index and an increase in
pulmonary functional residual capacity. An increased
risk of liver and spleen injury exists for upper pole punc-
ture with the patient supine. Potential injury to the
colon is greatest during prone lower pole access. A
greater surface area for percutaneous access exists with
the patient prone. The supine position decreases sur-
geon radiation exposure and promotes spontaneous
stone drainage during the procedure. Two comparative
series show that the supine position is associated
with significantly shorter operative time. In contrast,
noncomparative case series suggest decreased operative
time and blood loss when treating staghorn calculi with
the patient prone [114].
The supine position is also indicated in a high American
Society of Anesthesiologists (ASA) score [115]. Cracco
et al. and Kawahara et al. propose ECIRS (Endoscopic
Combined IntraRenal Surgery) is a new way of affording
PNL in a modified supine position, approaching antero-
retrogradely to the renal cavities, and exploiting the full
array of endourologic equipment. Supine PNL and ECIRS
are not superior to prone PNL in terms of urological
results, but guarantee undeniable anesthesiological and
management advantages for both patient and operators.
In particular, ECIRS requires from the surgeon a perman-
ent mental attitude to synergy, standardized surgical steps,
versatility and adherence to the ongoing clinical
requirements. ECIRS can be performed also in particular
cases, irrespective to age or body habitus. The use of flex-
ible endoscopes during ECIRS contributes to minimizing
radiation exposure, hemorrhagic risk and post-PNL renal
damage [116,117].
Percutaneous access
The debate over access numbers still continue. The
authors suggest that higher stone free rates could be eas-
ily obtained with the use of flexible nephroscopes during
the PNL [118,119]. Wong et al. reported a stone free
rate of 95% in patients treated with a single percutan-
eous tract with flexible nephroscopy. The use of a single
tract with high stone free rates seems the best achieve-
ment in terms of minimal invasiveness and the bench-
mark for procedure comparison [120]. Akman et al.
consider the impact of PCNL using either single or mul-
tiple access tracts on renal function, finding similar
results. By the way PCNL with multiple accesses is a
highly successful alternative with considerable complica-
tion rates in the management of staghorn calculi [121].
Li NL et al. propose percutaneous nephrolithotomy
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stone clearance rate due to its easy access into the
intrarenal collecting system and can be an ideal
approach for PCNL for complicated renal calculi [122].
PNL under local anesthetics
PNL under local anesthesia is a very attractive method
in order to minimize procedure morbidity. Indication
should be very strict and must exclude staghorn calculi
patients, previous renal surgery, and stone burden
>3.5 cm. Local anesthesia should also include percutan-
eous tract and renal parenchyma to achieve post-
operative pain control [123,124].
Robotic surgery
Robot-assisted laparoscopic surgery with the daVinci sys-
tem is immensely popular among urologists. However
some of the earliest experiences with robotics in urology
were developed by italian group of Bove in the last ’90.
They performed different kind of procedures (spermatic
vein ligation, retroperitoneal renal biopsy, simple neph-
rectomy and pyeloplasty) with the help of two robots:
AESOP for the orientation of the laparoscope and PAKY
to perform the percutaneous access [125]. Robot-
assisted surgery is now well-established in Urology and
although not currently regarded as a ‘gold standard’ ap-
proach for any urological procedure, it is being increas-
ingly used for index operations of the prostate, kidney
and bladder [126]. Fine movement control and drift-free
maintenance of the endoscope distal tip is typically
insufficient using manual control to perform complex
procedures. The aim of robotic surgery is to allow safer
and more homogeneous outcomes with less variability in
surgeon performance and reduced occupational radi-
ation exposure. Desai et al. tested on animals a new flex-
ible robotic system for performing retrograde intrarenal
surgery [127] and his initial clinical experience on 18
patient was encouraging: all procedures were technically
successful without conversion to manual ureteroscopy
and the complete stone clearance rate at 2 and 3 months
was 56% and 89%, respectively. At 3 months all patients
had stable renal function and unobstructed drainage
[128]. According to the authors, potential advantages of
the technique include increased range of motion, instru-
ment stability, and improved ergonomics.
The nascent field of flexible robotics appears to be
promising. Refinements in software and hardware are
needed to allow these systems to be used for natural
orifice transluminal surgery. A significant advance in
robotic surgery came from URobotics Laboratory at
Johns Hopkins (Baltimore, MD, USA), which recently
developed the AcuBot robot. This device is a fully
actuated driver for needle insertion, spinning, release,
and force measurement. This provides an additionalneedle support guide in close proximity to the skin entry
point. The device is the first promising step to a future
clinical application of robotic guided percutaneous renal
access [129].
“News from the past”
Recent research by Mariani assesses the feasibility of
ureteroscopic monotherapy of renal calculi >2 cm.
Lithotripsy was performed in 75 patients with a single
deflection flexible ureteroscope and predominantly
electrohydraulic lithotripsy; laser drilling was employed
to weaken very hard stones. Stone free status was
achieved in 96% of patients [130]. Recently, similar
results was obtained by Hyams et al.: one hundred and
twenty patients underwent URS/holmium laser litho-
tripsy for renal stones of 2 to 3 cm. One hundred and
one (84%) patients underwent single-stage procedures.
Conclusion
Urolithiasis is a growing problem in industrialized coun-
tries and is often correlated to typical Western patholo-
gies and habits such as diabetes, hypertension, high
purine intakes, obesity, and metabolic syndrome. Beside
drug treatment, in recent years medical therapies incorp-
orating herbal components known for centuries have
been investigated. Data show that it offers new advan-
tage in stone clearance after SWL or in spontaneous
stone expulsion. NCCT is nowadays the most useful
clinical tool in stone patients. Among all the minimally
invasive stone treatments, SWL is always the less inva-
sive one, and stone free rates with SWL are lower than
with more invasive treatments. Therapy choice should
include these considerations. Development of new tech-
nologies offers further advances in well-standardized
procedures such as PNL and SWL. Robotics seems the
most promising field capable of new developments in
ureterorenoscopy and percutaneous approaches.
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